Explore end-to-end solutions throughout development — from portfolio optimization and regulatory strategy, to Phase I-IV clinical trials, market access planning, and more.
See solutionsWHAT WE DO
HOW WE DO IT
Parexel Biotech provides the end-to-end capabilities you’ll need to succeed. We're fast, flexible, and dedicated to impacting patient lives.
Learn moreUtilize our expertise across therapeutic areas, combining innovative trial designs, leading clinical and regulatory expertise, global reach, and a passion for changing patient lives.
See expertiseTherapeutic Expertise
Cross-Therapeutic Expertise
Our experts help you stay at the forefront of the industry - and ahead of change.
See insightsNew Medicines, Novel Insights
Discussions on Diversity
The Regulatory Navigator
Thinking about joining a clinical trial? Learn the drug development process, what it’s like to participate, how to find a trial, and answers to frequently asked questions.
Learn moreINTERESTED IN PARTICIPATING?
HEAR FROM REAL PATIENTS
TRIAL SITES
Want to collaborate with us to offer clinical trials at your site? We would welcome the opportunity to discuss.
Learn moreWe are one of the largest CROs in the world, speeding life-changing medicine to market by engaging patients With Heart™. Learn about who we are, what we do, and what we believe.
About ParexelWhat can we help you find today?
Design and execute oncology trials faster than ever
At Parexel, we propel your research forward by combining an early advisory service of medical, regulatory, genomics, and biostatistical experts with an experienced multidisciplinary team and key technology partnerships. We’re equipped with the experience and expertise to support you in treating all major types of cancer, across every phase of development — so your treatment gets to patients faster.
Our Oncology Center of Excellence includes more than 80 ex-agency regulators from FDA, EMA, NMPA, MHRA, and PEI, among other bodies, as well as six ex-FDA regulators from CBER’s Office of Tissues and Advance Therapies and the former Deputy Center Director of the FDA’s Oncology Center of Excellence. Our insights about highly specific regulatory processes and requirements, as well as our ongoing relationships with current regulators, help bring your breakthrough treatments to market faster.
I am so passionate about the science. It is the entire reason I trained as an oncologist.
I was a basic researcher for some time and it is the science that really drives me every day to come to work with a happy smile. When I was in high school my best friend was diagnosed with lymphoma. It got me interested in oncology in the first place.
And then the science is what nailed the deal. And I think it's really important to listen to the patients to understand what "clinical benefit" means to them. I'm really proud that Parexel is doing this. It's involving patients more and more in all of the interactions with the clients, with the studies, with strategies to help run studies more efficiently so that the patients want to enroll and stay in studies throughout to the end.
Something that I was aware of was a study we did in breast cancer. It was a study that's going to be submitted to regulatory agencies for approval as a new therapy. And it really can shift how a breast cancer patient receives that therapy. Instead of having to take a shot, they can take a pill, which is a lot easier.
Not only did we run this study and have it submitted to the regulatory agency FDA, but we also just found out recently that it got approval.
I have every faith that all of our medics are experts in their field and can provide our clients with the best advice and the best run studies in the industry. And that's really the building block of a relationship.
Our team of specialists provides comprehensive support for clinical trials in both benign conditions and hematologic malignancies, covering all stages from first-in-human to post-registration studies.
Our expertise extends to areas such as targeted therapies, immune-oncology, cell and gene therapy, and bone marrow transplantation.
Breast and gynecologic cancers are active areas of clinical research at Parexel. We understand the significant impact these diseases have on women's health and are deeply committed to combating women's cancer.
Our global studies have made significant advancements in maintenance therapy following chemotherapy, increasing the duration of remission.
We are actively involved in numerous trials for evaluating new and promising agents in colon cancer and pancreatic cancer, which continue to be significant contributors to cancer morbidity.
We have witnessed notable progress in the use of immunotherapy, particularly in front-line therapy for advanced gastric cancer and postoperative therapy for resected esophageal cancer.
Our dedicated genitourinary cancer specialists are committed to introducing innovative treatments to patients and facilitating a wide range of clinical studies.
With extensive expertise in various indications and with diverse investigational compounds, our experienced team, located in Europe, North America, and the APAC region, ensures global accessibility and delivers exceptional medical oversight and monitoring for awarded studies.
Our dedicated team of lung and head and neck cancer specialists conducts a comprehensive range of clinical studies, including early phase to Phase III trials and post-approval safety trials.
With our experienced team and global presence, we strive to bring hope and innovative treatments to patients in need.
Our Phase I and rare tumors team is a diverse group of experts with backgrounds in pediatric oncology, clinical pharmacology, and early phase research.
We're experienced in both standard rule-based escalation designs and Bayesian model-based designs and excel in complex adaptive trial designs.
Advantages
Our oncology team is 1,000+ strong, including 45+ physicians with oncology experience, expertise in China and Japan, and recent key medical oncologist and ex-FDA appointments. Our clinical trial work is particularly noteworthy in the indications listed above, with experience with multiple cell and gene therapies as well.
We have access to nearly 2,500+ sites across Phase I-III solid tumors trials globally. From this number we have established strategic relationships with more than 220 solid tumor experienced sites that are part of Parexel Site Alliance network — sites that have achieved high levels of investigator satisfaction, improved number of patients recruited per site, and accelerated timelines thanks to the alignment of startup processes.
Through social listening, patient surveys, and patient burden analysis, we continually collect oncology patient insights to assess trial feasibility, improve study design, and identify risk. These practical, actionable insights help us to create more accessible trials, reduce trial amendments, increase enrollment, and improve the patient experience. These insights, when combined with our innovative recruitment and retention strategies, allow us to deliver results that exceed your expectations.
Our innovative approaches include adaptive designs; basket, umbrella, and platform studies; and model-based dose escalation trials. We also develop strong relationships with best-in-class partners pushing the boundaries of what technology can do. With innovations like artificial intelligence and machine learning, as well as streamlined data collection and reporting, we reliably deliver more efficient designs, site selection processes, recruitment strategies, and more.
